- Home
- XERS
as 08-27-2025 4:00pm EST
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
| Founded: | 2005 | Country: | United States |
| Employees: | 394 | City: | CHICAGO |
| Market Cap: | 1.3B | IPO Year: | 2018 |
| Target Price: | $8.00 | AVG Volume (30 days): | 3.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.48 - $8.02 | Next Earning Date: | 08-07-2025 |
| Revenue: | $246,025,000 | Revenue Growth: | 35.62% |
| Revenue Growth (this year): | 43.89% | Revenue Growth (next year): | 20.40% |
Stock Insider Trading Activity of Xeris Biopharma Holdings Inc. (XERS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| JOHNSON JOHN | XERS | N/A | Aug 13 '25 | Sell | $7.32 | 107,500 | $786,459.25 | 833,483 | |
| HALKUFF DAWN | XERS | N/A | Aug 12 '25 | Sell | $7.28 | 42,500 | $309,225.75 | 115,000 | |
| McCulloch Kevin | XERS | See Remarks | Jun 13 '25 | Buy | $4.38 | 25,000 | $109,475.00 | 1,708,585 |
Latest Xeris Biopharma Holdings Inc. News
XERS Breaking Stock News: Dive into XERS Ticker-Specific Updates for Smart Investing
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 06/17/2025
MT Newswires
3 months ago
Xeris Biopharma Holdings Shares Fall; 2025 Revenue Guidance Reaffirmed, Long-Term Outlook Set
Business Wire
3 months ago
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
Business Wire
3 months ago
Xeris Announces Details for Analyst & Investor Day
Insider Monkey
4 months ago
Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now
Simply Wall St.
4 months ago
Xeris Biopharma Holdings First Quarter 2025 Earnings: Beats Expectations
GuruFocus.com
4 months ago
Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...
Zacks
4 months ago
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates
Compare XERS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XERS Xeris Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.